These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26535978)

  • 1. The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.
    Raanani P
    Acta Haematol; 2016; 135(3):131-2. PubMed ID: 26535978
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
    Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
    Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
    Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
    [No Abstract]   [Full Text] [Related]  

  • 4. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
    Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
    Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
    [No Abstract]   [Full Text] [Related]  

  • 5. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
    Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
    Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
    [No Abstract]   [Full Text] [Related]  

  • 6. Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
    Angriman F; Gutierrez Acevedo MN; Rossi MS; Gimenez Conca AD; Otero V; Arbelbide JA; Michelángelo H
    Turk J Haematol; 2015 Jun; 32(2):193-4. PubMed ID: 26316496
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
    Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
    Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
    Gambacorti-Passerini C; Piazza R
    JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
    Lee SE; Choi SY; Song HY; Kim SH; Choi MY; Park JS; Kim HJ; Kim SH; Zang DY; Oh S; Kim H; Do YR; Kwak JY; Kim JA; Kim DY; Mun YC; Lee WS; Chang MH; Park J; Kwon JH; Kim DW
    Haematologica; 2016 Jun; 101(6):717-23. PubMed ID: 26888022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Happens When Imatinib Goes Generic?
    McDougall J; Ramsey SD; Radich J
    J Natl Compr Canc Netw; 2016 Feb; 14(2):128-31. PubMed ID: 26850483
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
    Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
    Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology of CML supports second-generation TKIs as frontline treatment.
    Fava C; Saglio G
    Clin Adv Hematol Oncol; 2017 Apr; 15(4):302-307. PubMed ID: 28591106
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
    Shi CR; Nambudiri VE
    Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
    [No Abstract]   [Full Text] [Related]  

  • 15. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
    Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
    Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolution of Roth spots in chronic myeloid leukaemia after treatment with imatinib.
    Docherty SM; Reza M; Turner G; Bowles K
    Br J Haematol; 2015 Sep; 170(6):744. PubMed ID: 26119417
    [No Abstract]   [Full Text] [Related]  

  • 17. Pediatric chronic myeloid leukemia with myeloid blast crisis and complex karyotype at presentation.
    Sazawal S; Singh K; Chhikara S; Chaubey R; Mishra P; Seth T; Saxena R
    Indian J Cancer; 2020; 57(3):343-345. PubMed ID: 32769290
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
    Sazawal S; Chikkara S; Singh K; Chaubey R; Chandra D; Mishra P; Mahapatra M; Seth T; Saxena R
    Ann Diagn Pathol; 2017 Apr; 27():24-27. PubMed ID: 28325357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
    Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
    Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.